Efficacy and safety of duloxetine for depression in China :a meta-analysis
10.3760/cma.j.issn.1674-6554.2018.09.018
- VernacularTitle:度洛西汀治疗抑郁症临床疗效及安全性国内研究的meta分析
- Author:
Jianfeng ZHU
1
;
Weidong JIN
;
Fengli SUN
Author Information
1. 浙江中医药大学第二临床学院
- Keywords:
Duloxetine;
Depression;
Meta analysis;
Double-blind randomized controlled trials;
Efficacy;
Safety
- From:
Chinese Journal of Behavioral Medicine and Brain Science
2018;27(9):858-864
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically evaluate the efficacy and adverse effects of duloxetine in the treatment of domestic depression patients,and compare with those who were treated with SSRIs drugs in the same period to explore the difference between them to guide the clinical medication.Methods A search was conducted in CBMdisc,Wanfang database,CNKI,VIP,Pubmed.The double-blind randomized controlled trials on duloxetine for depression in China were collected.The quality of the included trials was assessed according to the Cochrane Handbook 5.0,and the systematic analysis was conducted by using RevMan 5.3 soft ware.Results Seven double-blind randomized controlled trials (two of duloxetine versus fluoxetine,five of duloxetine versus paroxetine) involving 1 193 patients were included.The results of rmeta-analysis showed that:①After 6-8 weeks of treatment,there were no significant differences in the effective rate (RR =1.02,95％CI=0.78-1.32,Z=0.12,P=0.90),and the final cure rate (RR=0.95,95％CI=0.75-1.19,Z=0.47,P=0.64) between the duloxetine and fluoxetine/paroxetine groups.②Adverse reactions:the incidence rate was not significantly different between duloxetine and fluoxetine/paroxetine groups (RR =1.03,95％ CI =0.86-1.23,Z=0.32,P=0.75).Conclusion After 6-8 weeks of treatment,there are no significant differences in the effective rate and the final cure rate between duloxetine and fluoxetine/paroxetine.There is no significantly difference in common adverse reactions.
